Replies to post #5594 on Enanta Pharmaceuticals Inc (ENTA)

[DewDiligence]

The underwriting agreement was signed by_all_parties_on 9/30/25:

https://www.sec.gov/Archives/edgar/data/1177648/000119312525226828/d81869dex11.htm (body of underwriting agreement)

https://www.sec.gov/ix?doc=/Archives/edgar/data/0001177648/000119312525226828/d81869d8k.htm

On September 30, 2025, Enanta Pharmaceuticals, Inc. (“Enanta”) entered into an underwriting agreement (the “Underwriting Agreement”) with J.P. Morgan Securities LLC, Jefferies LLC, and Evercore Group L.L.C., as representatives of the several underwriters named therein (collectively, the “Underwriters”), relating to the issuance and sale in a public offering of 6,500,000 shares of Enanta’s common stock, par value $0.01 per share (the “Common Stock”). The price to the public in the offering was $10.00 per share. In addition, Enanta granted the Underwriters an option, exercisable for 30 days, to purchase up to 975,000 additional shares of Common Stock at the public offering price, less the underwriting discounts and commissions.

[alertmeipp]

You just never know, here was the RVNC timeline. All in 3 months. So we could get a buyout Oct/Nov 😀

On February 2, 2024, Party B, a strategic party, executed a non-disclosure agreement with Revance (the “Party B NDA”) in connection with Party B’s consideration of a potential strategic transaction with, or investment in, Revance.

On March 4, 2024, Revance announced the pricing of an underwritten public offering of 16,000,000 Shares at a public offering price of $6.25 per share (except with respect to 30,000 Shares purchased by Mr. Foley at $6.98 per share).

On April 3, 2024, Revance received a non-binding proposal from Crown indicating Crown’s interest in pursuing an acquisition of Revance for $9.25 per share in cash,